Organotypic 3D Assay Platforms In Development
“The development of physiologically relevant models should recognise that organs and tissues function in a 3D environment… and in the final analysis, the organ itself is the unit of function.”
Schmeichel & Bissell, 2003
Advantages of the OrganDOT™ System
- 3D microtissues recapitulate original tissue architecture and functionality
- Robust function, longevity.
- Compatible with multiple endpoint assays such as: mediator release, cell viability/proliferation/apoptosis, ICC & qRT-PCR
- Simultaneous testing of multiple treatments and schedules delivers comprehensive compound profiles within a shorter time period
- Established isletOrganDOT™
- Potential to be applied to different cell type systems
- Liver (hepatocyte, stellate and Kupffer cell co-culture)
- Lung (tumor cells + CAFs co-culture)
Asterand Bioscience received funding in September 2014 from the UK Technology Strategy Board (Innovate UK) to lead the development of a 3D multicellular liver fibrosis model. We are collaborating with the University of Manchester for the parallel evaluation of a matrix-free (OrganDOT™) and matrix-based (RAFT™) platform.
Asterand Bioscience is developing 3D human primary multicellular oncology models using the OrganDOT™ platform. Initial development work has been completed using a lung cancer cell line. Asterand Bioscience has also used soft gel 3D culture approaches for the co-culture of primary tumor epithelial cells + cancer associated fibroblasts (HuCAFs).
Human lung cancer cell line forms 3D aggregates in the OrganDOT™ platform. These cells express the epithelial marker cytokeratin and remain viable over long-term culture.
Effects of the apoptosis inducer staurosporine on human lung cancer cell line in OrganDOT™ culture. Staurosporine induces caspase activity and causes loss of cell viability in 3D cultures of human tumour cells.